| Names | |
|---|---|
| Preferred IUPAC name | Methyl 3,3,3-trifluoro-2-oxopropanoate |
| Other names | Methyl 3,3,3-trifluoro-2-oxopropanoate Methyl trifluoropyruvate Methyl 2-oxo-3,3,3-trifluoropropanoate TFPA methyl ester |
| Pronunciation | /ˈmɛθɪl ˌθriː θriː θriː traɪˈflʊəroʊ paɪˈruː.veɪt/ |
| Identifiers | |
| CAS Number | 430-59-1 |
| 3D model (JSmol) | `JSmol` string for **Methyl 3,3,3-trifluoropyruvate (M-TFPA)** (commonly represented as C4H3F3O3): ``` CC(=O)C(=O)OC(F)(F)F ``` |
| Beilstein Reference | 1209223 |
| ChEBI | CHEBI:139443 |
| ChEMBL | CHEMBL1493545 |
| ChemSpider | 21544197 |
| DrugBank | DB08343 |
| ECHA InfoCard | 01-2120766770-47-0000 |
| EC Number | 208-011-1 |
| Gmelin Reference | 107218 |
| KEGG | C18632 |
| MeSH | D016962 |
| PubChem CID | 131101 |
| RTECS number | YK7878000 |
| UNII | N4U9QT0D5F |
| UN number | 3272 |
| CompTox Dashboard (EPA) | DTXSID50884413 |
| Properties | |
| Chemical formula | C4H3F3O3 |
| Molar mass | 150.07 g/mol |
| Appearance | Colorless to light yellow liquid |
| Odor | Pungent |
| Density | 1.456 g/mL at 25 °C (lit.) |
| Solubility in water | Soluble |
| log P | -1.01 |
| Vapor pressure | 0.5 hPa (20 °C) |
| Acidity (pKa) | pKa = 7.3 |
| Basicity (pKb) | 15.51 |
| Magnetic susceptibility (χ) | χ = -36.86 × 10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.3520 |
| Viscosity | 1.233 cP (25 °C) |
| Dipole moment | 2.45 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 309.6 J/mol·K |
| Std enthalpy of formation (ΔfH⦵298) | -708.7 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | –1141 kJ·mol⁻¹ |
| Hazards | |
| GHS labelling | GHS02, GHS07 |
| Pictograms | GHS05, GHS07 |
| Signal word | Danger |
| Hazard statements | H226, H302, H315, H319, H335 |
| Precautionary statements | P261, P264, P271, P272, P280, P301+P312, P302+P352, P305+P351+P338, P312, P321, P330, P337+P313, P362+P364, P501 |
| Flash point | Flash point: 39 °C |
| Autoignition temperature | 315 °C |
| Lethal dose or concentration | LD50 oral rat 2510 mg/kg |
| NIOSH | Unlisted in NIOSH |
| PEL (Permissible) | Not established. |
| REL (Recommended) | 0.005 ppm |
| IDLH (Immediate danger) | No IDLH established. |
| Related compounds | |
| Related compounds | Ethyl 3,3,3-trifluoropyruvate 3,3,3-Trifluoropyruvic acid Methyl pyruvate Pyruvic acid Ethyl pyruvate Methyl 2-oxobutyrate |
| Parameter | Details | Technical Commentary |
|---|---|---|
| Product Name | Methyl 3,3,3-trifluoropyruvate | This nomenclature follows established IUPAC recommendations. The product’s core feature, the trifluoromethyl group, is central to its performance in fluorochemical synthesis and agrochemical intermediate applications. |
| IUPAC Name | Methyl 3,3,3-trifluoro-2-oxopropanoate | Production documentation relies on the IUPAC systematic name for batch tracking and regulatory dossiers. Purchasers referencing international databases usually require precise IUPAC format for regulatory submissions and synthesis planning. |
| Chemical Formula | C4H3F3O3 | Process control in manufacturing hinges on strict stoichiometric balance. Excess reactants and byproduct formation impact batch purity. Analytical confirmation of the formula’s integrity supports release testing and downstream suitability. |
| CAS Number | 13089-17-7 | Global trade and compliance require this identifier for customs entry, chemical inventory, and import/export declarations. Consistency in labeling helps internal traceability and supports customers in regulatory reporting. |
| Synonyms & Trade Names | M-TFPA; Methyl trifluoropyruvate; Methyl 3,3,3-TFP; Pyruvic acid, 3,3,3-trifluoro-, methyl ester | Synonyms reflect historical naming practices and regional preferences. Each synonym may indicate origin of process, application focus, or customer ordering terminology. Accurate synonym records streamline contract review and supply chain documentation. |
| HS Code & Customs Classification | 29163990 (Ester derivatives of carboxylic acids with oxygen function; not elsewhere specified) | Classification aligns with international tariff coding for esters. The manufacturing records must specify the HS code on waybills, export licenses, and shipping safety documentation. Regional variations in customs treatment could require additional sub-coding, all determined by the main raw material (trifluoroacetylating agent) and the esterification product profile. |
| Aspect | Manufacturer Perspective |
|---|---|
| Raw Material Selection | Selection involves sourcing fluorinated building blocks with verifiable origin and impurity profiles. Minor contaminants from starting esters or fluorination agents can persist through to the final stage, impacting analytical values and suitability for synthesis. |
| Process Route | The favored route involves transesterification or direct fluorination depending on availability of precursors. Route selection impacts cost, impurity spectrum, and required purification steps. Batch-to-batch consistency calls for strict adherence to chosen synthetic methodology, as minor route drift can change analytical impurity profile. |
| Key Controls & In-Process Tests | Main controls include reactant conversion by instrumental analysis and real-time moisture content measurement. Intermediate checks are conducted using GC and NMR to spot hydrolytic byproducts or unreacted starting materials, assisting in minimizing off-spec batches. |
| Purification & Batch Consistency | Typical purification involves phase separation followed by distillation under reduced pressure. The distillation fraction cut points are defined internally after qualification runs. Stringent fraction collection is essential — trace carryover of starting material or high-boiling residues leads to downstream processing difficulties for end users. |
| Release Criteria | Release is governed by in-house control limits for assay, moisture, residual solvents, and volatile impurities. Customers in pharmaceuticals or fluorochemical synthesis occasionally specify additional criteria, such as heavy metals or specific low-level byproducts. Actual values depend on customer specification and application destination. |
| Property | Grade-Dependency / Application Sensitivity | Storage, Handling, and Downstream Implications |
|---|---|---|
| Appearance | Typically a clear, colorless to pale yellow liquid. Trace color varies based on precursor purity and storage. Customers using for pharmaceutical synthesis usually require narrower color specification. Agrochemical intermediates tolerate broader range. | Extended exposure to light or high temperatures accentuates color development. Air exclusion is advised as per internal best practices to minimize oxidative color change. |
| Assay (purity) | Assay is grade-defined. Pharmaceutical/intermediate grades are released to tighter assay limits compared to technical or bulk grades. Actual values and acceptance criteria are application and customer driven. | Lower purity fractions can introduce unpredictability into end-use reactions, causing increased rework or wasted batches. Released lots for regulated applications are dispatched with full COA batch traceability. |
| Impurities | Key impurities include unreacted ester, hydrolyzed acids, and minor fluorinated byproducts. The impurity cutoff aligns with customer demand and application. Each production run reports detailed impurity profiles for contract customers. Market grade primarily summarizes by GC area percent. | Higher impurity content may impede formulation stability and downstream chemical transformations, especially where condensation or nucleophilic substitution is used. Companies formulating for high-purity or regulated markets specify lower limits. |
| Storage Requirements | Not grade-specific. Protection from moisture ingress and air is routine, as hydrolysis risk presents for all industrially marketed grades. | Operations maintain dry nitrogen padding for drum or can shipments. Small pack customers receive product pre-sealed in moisture-barrier containers and must avoid repeated drum opening. |
| HS Code Application | The assigned HS code pertains to ester derivatives. Specialty applications may require supporting dossiers to satisfy local authorities. Pharmaceutical shippers often append additional documentation outlining impurity and process controls. | Customs clearance relies on uniform classification, avoiding detention and unnecessary analytical holds in the supply chain. |
Methyl 3,3,3-trifluoropyruvate typically presents as a clear to pale yellow liquid under standard ambient conditions. The odor profile may be characterized by a faint ester-like smell, although the perception varies according to purity and presence of trace byproducts. Physical form and color can exhibit minor shifts based on production batch and residual moisture or solvent content. Melting and boiling points fall within a range defined by grade and residual impurities, which can shift phase transition characteristics. Density depends on temperature and minor constituents, so routine batch analysis is essential for process integration. End-user formulation and blending reactions demand close monitoring, as volatility or trace water content may affect downstream performance.
The trifluoroacetyl group endows the molecule with heightened electrophilicity, affecting its compatibility with nucleophilic components. Both stability and reactivity reflect the synthesis route and storage discipline. Sensitivity to hydrolysis, especially in the presence of atmospheric moisture, increases the risk for acid formation over time. Generating environments with inert atmospheres can help maintain product integrity against oxidative or hydrolytic degradation. Storage and handling should avoid basic conditions, as enolization and subsequent decomposition could impact overall purity.
Solubility behavior depends on solvent class and target use. M-TFPA mixes readily with most polar organics, such as alcohols and esters. Water miscibility remains limited due to the trifluoromethyl group, with potential for slow hydrolysis in aqueous phases. For applications demanding precise solute concentrations, solution preparation techniques should account for both volatility and reactivity, especially when exposed to base or acid. Avoiding moisture ingress during dispensing and transfer upholds both analytical accuracy and reagent shelf life.
Manufacturers assign specification targets according to customer requirements, end-use sector, and synthesis method. Purity standards, water content, and residual solvent thresholds all fluctuate depending on whether the intended application is agrochemical synthesis, pharmaceutical intermediate, or materials R&D. Typical values are set following internal process capability and consensus testing. Every batch must meet or exceed contractual grade parameters before release.
The principal concern in impurity monitoring centers around unreacted starting esters, partially fluorinated ketones, and traces of inorganic acid or residual solvents. Each class of impurity carries implications for stability, reactivity, and safety, especially in catalytic or cGMP contexts. Manufacturers design test panels to capture both process-derived contaminants and those arising from storage degradation. All limits are harmonized with batch use, downstream reaction sensitivity, and user-specific risk-reduction expectations. Final acceptance criteria are aligned with customer and internal protocols.
Routine quality control embraces analytical techniques responsive to grade specifics—GC, NMR, and KF titration for water content together form the core, with expanded tests for metals or chromatographic fingerprinting as determined by application sector. Reference standards and method validation exercises are benchmarked to both industrial best practice and regulatory expectations. Batch testing frequency and protocol depth reflect both volume and destination market stringency.
Raw material selection revolves around achieving consistent trifluoroacetyl and methylation sources with tightly controlled impurity backgrounds. Global sourcing strategies anchor to suppliers demonstrating traceability, audit compliance, and technical collaboration to support custom grade demand. Certification for critical attributes (water content, trace metals) is reinforced by incoming QC analytics.
Industrial production typically follows an esterification or transesterification pathway, using a methylating agent reacting with a trifluoropyruvic acid precursor. Process route selection is swayed by desired impurity profile and cost-performance balance. Side reaction minimization, especially hydrolysis and over-alkylation, forms the bulk of process engineering effort. Reaction parameters—solvent choice, temperature, stoichiometry—adjust according to batch scale and downstream use priorities.
Process reliability depends heavily on controlling exothermicity and preventing ingress of water or reactive impurities. Inline analytical tracking, by GC or spectroscopic means, supports endpoint determination. Purification spans distillation, vacuum stripping, and adsorptive treatments; protocol is tailored by downstream specification, with tighter cuts for pharmaceutical routes. Material transfer maintains nitrogen or argon blankets in moisture/pH-sensitive contexts. Manufacturers tie purification method to end specification, as batch-to-batch consistency directly affects customer process fit.
Each lot undergoes comprehensive analysis for appearance, purity, moisture, and RRT impurity content. Microbatch or continuous process outputs follow separate release tracks, with documentation stacking traceable in both GMP and non-GMP scenarios. Final release standard is set by internal criteria and, where stipulated, by explicit customer contract.
The strong electron-withdrawing effect of the trifluoromethyl group informs how M-TFPA functions in condensation, nucleophilic addition, and reduction steps. The methyl ester group is labile under both acidic and basic catalysis, which gives the product value in multistep synthesis. Process chemists frequently tap into its reactivity for α-substitution and heterocycle synthesis, leveraging the heightened electrophilicity of the keto carbon.
Catalyst selection, solvent systems, and temperature regime vary with downstream target and desired selectivity. Both homogeneous and heterogeneous base or acid catalysts see use, with temperature control aimed at balancing conversion efficiency and byproduct management. The main challenge for process scale-up comes from volatility and hydrolytic sensitivity, necessitating continuous monitoring and, where required, closed-loop environmental controls.
In industrial synthesis, M-TFPA serves as a key precursor for generating fluorinated heterocycles and other high-value building blocks. Derivatization opportunities expand across nucleophilic additions, enolate chemistry, and controlled reduction, among others. The breadth of downstream conversion is shaped by customer project trajectory and regulatory backdrop, which together dictate both process optimization and impurity minimization strategies.
Maintaining product integrity requires cool, dry storage—ideally under inert gas, with minimal exposure to strong light or alkaline vapors. High ambient humidity or cycling temperatures prompt premature hydrolysis, turning the product acidic and affecting both usability and safety. Each customer-facing storage recommendation factors local climate and transport logistics into the risk mitigation plan.
M-TFPA generally shows compatibility with fluoropolymer- or glass-lined packaging. Interaction with standard steel or aluminum, especially under damp conditions, may promote surface corrosion or local degradation. Container type and closure configuration tie back to both batch size and anticipated transit duration.
Recommended shelf life stands as a function of storage condition, container integrity, and initial batch water content. Product freshness is tracked through scheduled re-analysis; off-spec odor, increased acidity, or phase separation signal potential degradation and merit retesting prior to use in sensitive synthesis.
Global GHS labeling focuses on acute toxicity and the potential for respiratory, dermal, or eye irritation. Manufacturer hazard communication is updated in light of ongoing toxicological assessment, harmonized regionally to regulatory norms.
Exposure control targets both inhalation and skin contact routes. Operators engage both engineering and personal protection, with gloves and goggles considered standard. Local exhaust ventilation, liquid-tight transfer, and spill containment together form a coherent practice in manufacturing zones.
Toxicological understanding remains route- and dose-dependent. Manufacturers monitor for both acute symptoms and low-dose chronic exposure signals in the workforce. Available animal study data guide risk assessment, with periodic review of findings shaping both plant policy and customer advisories.
Internal plant controls set airborne and surface exposure tracking as part of standard operating procedure. Threshold values align with published best practice and are supplemented by real-time monitoring for process deviations. Employees receive regular training in risk recognition, first response, and decontamination protocols to reduce both acute and chronic exposure risk.
Annual output of M-TFPA is driven by the qualification and sourcing strategy for upstream precursors, including hydrofluorocarbons and pyruvate derivatives. The continuous batch system determines capacity fluctuations according to reactor maintenance schedules and purification queue availability. Production runs prioritize pharmaceutical and agrochemical grades during periods of tight demand, with research and lower-volume grades on flexible schedules. Wide monthly variations in demand from custom synthesis customers can reduce short-term allocation for spot purchases.
Lead times strongly depend on grade, purity, and documentation requirements. For standard technical grade, typical lead times after order confirmation range from two to six weeks, factoring in queue management and downstream purification/uplift steps. For pharmaceutical applications requiring validated change control and multi-stage release, lead times can extend to several months depending on customer auditing and intermediate inventory policies. MOQ is grade-dependent: for industrial applications, the typical MOQ aligns with a full reactor charge or drum volume, while custom packaging can affect both MOQ and delivery lead time.
Packaging is tailored according to sensitivity to light, moisture, and potential cross-contamination, with options such as fluoropolymer-lined drums, HDPE bottles, and inerted stainless steel containers for high-purity grades. Pharmaceutical-grade product typically ships in double-sealed packaging with lot traceability and chain-of-custody labeling. For bulk industrial grades, standard fiber drums with inner liners provide adequate stability for typical transit durations.
For export, shipments follow IMDG and IATA requirements where applicable. Incoterms are negotiated per customer risk profile. Phased payment arrangements can be granted for long-term supply agreements, while ad hoc spot purchases typically require advance or immediate payment. Samples and documentation may be included in first-time shipments to facilitate customer in-house validation.
Cost structure for M-TFPA centers on the volatility of fluorinated raw materials and base pyruvate feedstock, often subject to market disruptions or regulatory control. Procurement risk is elevated for any fluoro-organic intermediates with tight restrictions or single-source vulnerabilities. Shifts in global HFC (hydrofluorocarbon) prices, environmental fee structures, and regional sourcing disruptions contribute to cost variation, usually reflected immediately in spot pricing and within six-month terms for contract customers.
Pricing aligns with internationally recognized grades. Higher pricing for pharmaceutical and regulatory-compliant grades comes from batch documentation, multi-stage QC testing, validated cleaning procedures, and impurity profiling (below customer-specified limits) which increase cost per batch. Technical grades command lower pricing due to relaxed release standards and less detailed documentation, but potential variability in side-products may require additional downstream processing by the end user.
Raw material prices react quickly to:
Price scaling between grades is largely determined by:
Demand for M-TFPA has seen year-on-year growth in pharmaceutical intermediate and agrochemical market segments. The majority of installed capacity sits in East Asia, with growing inventory risk from North American and European customers due to logistics disruptions. Several producers hold regional supply dominance, especially in the Chinese market, facilitated by access to key fluoro-organic building blocks. Inventory cycles peak during northern hemisphere planting and pharmaceutical production campaigns, causing recurring seasonal price peaks.
US: Regulatory-driven sourcing pushes buyers toward domestic or NAFTA-compliant producers. Import duties on Chinese fluorochemicals have increased landed cost variability.
EU: REACH compliance restricts sourcing to pre-registered or full dossier suppliers, tightening available inventory for new industrial applications.
JP: Stable sourcing but subject to periodic production outages at key fine chemical makers; strict internal audit and release processes increase lead time.
IN: Growing capacity but backward integration for fluoro-intermediates is limited, causing exposure to global HFC supply swings.
CN: Largest installed capacity. Rapid expansions and regulatory campaigns on environmental discharges can halt output with little advance warning, causing spikes in offshore pricing.
Current market indicators suggest sustained upward pressure into 2026, driven by a combination of tightening HFC quotas, expanded pharmaceutical pipeline projects, and enhanced discharge treatment requirements in key producing regions. Price stability remains more feasible for long-term contract customers with volume-linked purchasing power. Short-term or spot purchases can expect volatility linked to upstream feedstock and energy prices.
Market analysis leverages internal production statistics, major industry reporting services, regulatory notifications, quarterly customer feedback, and comparative analysis of inventory and lead time trends. Price forecasting relies on historical raw material volatility models, publicly available customs/shipment data, and projected regulatory changes affecting supply chain costs.
Recent years saw capacity expansion projects in East Asia and South Asia, partially offset by unplanned shutdowns tied to stricter local environmental inspections. Introduction of traceability and digital batch release systems in advanced economies has prompted tighter documentation and certification demand from all export markets. Customer interest in renewable precursor options is driving early-stage R&D but has not yet affected commercial output.
Tighter regulation of fluorochemical effluents across China and the EU has resulted in mandatory process upgrades and greater batch-to-batch variance in availability. Enhanced documentation requests for pharma and electronic grades reflect the increasing focus on extractable and leachable analysis. Large customers now require annual supplier compliance audits and transparent process change notification.
Process intensification projects aim to improve yield and impurity control while reducing effluent load. Redundant sourcing and multi-site production strategies are under review to respond to regulatory or supply chain disruptions. Advance order and blanket contract models allow both parties to buffer against sudden price or supply shocks in high-volatility periods.
M-TFPA serves as a core intermediate in both pharmaceutical and agrochemical synthesis. Its trifluoromethyl group contributes to bioactivity modification and metabolic stability—crucial features for advanced active pharmaceutical ingredients and specialty crop protection agents. In medicinal chemistry, it supports the construction of alpha-trifluoromethyl carbonyl building blocks. Fine chemical and electronic material sectors utilize M-TFPA in niche formulations, mainly for its reactivity profile and fluoroalkyl functionality.
| Application Segment | Recommended Grade(s) | Critical Quality Attributes |
|---|---|---|
| Pharmaceutical Synthesis | Pharma Grade | High assay (typically >98%), close impurity control (by HPLC/GC), trace metal limits, compliance with cGMP, solvent residue specified by ICH Q3C |
| Agrochemical Intermediate | Technical/Agro Grade | Minimum assay (typically >97%), agro-specific impurity limits, absence of class I/II solvents, batch-to-batch reproducibility |
| Fine Chemicals & Electronics | Specialty/Electronic Grade | Assay suited to downstream needs, low ionic contamination, moisture thresholds, customer-specific purity parameters |
| Key Parameter | Pharma Grade | Agro Grade | Specialty/Electronic Grade |
|---|---|---|---|
| Assay (%) | Defined per pharma standards, typically above 98 | Typically above 97 | Determined by end-use and processing route |
| Impurities (by HPLC/GC) | Tight individual and total limits, aligned to regulatory filings | Application-driven, less stringent than pharma | Selected based on downstream sensitivity |
| Residual Solvents | Per ICH Q3C guidance | targeted by sector-specific thresholds | Controlled by customer request |
| Moisture Content | Controlled to pharmaceutical standards, packaging in inert atmosphere | Preventing hydrolysis, standard drum packing | Low ppm level if specified |
Start selection by pinpointing your intended downstream process—API synthesis, crop protection formulation, or electronic intermediate. For regulated use (pharma, food contact), always document the specifics of your end-use to guide grade assignment.
Document any region- or market-specific compliance, such as GMP for pharmaceuticals or REACH for industrial markets. Regulatory drivers dictate quality attributes, from residual solvent guidance to impurity profiling, and influence the analytical suite applied during manufacturing release.
Different end uses have different assay and impurity cutoff values. Pharma applications drive the need for trace-level impurity disclosure and tight control, demanding advanced purification and batch tracking. Agrochemical and industrial segments accept higher impurity ranges, but batch consistency remains pivotal for process compatibility.
Volume requirements inform batch size planning and production scheduling. Larger lot sizes can support technical or agro grade selection, while high-assay pharmaceutical grade production often operates in smaller, more tightly controlled campaigns. Budget and lead time expectations should be balanced against the effort and controls needed to meet the grade.
Pilot testing on commercial samples is critical. M-TFPA often exhibits sensitivity to storage time and packaging conditions, influencing product color and stability, especially for high-purity requirements. Our technical support coordinates shipment under conditions reflecting production emissions, so end-users can validate processing compatibility before full-scale supply.
Raw inputs such as methyl trifluoroacetate and corresponding pyruvate precursor are evaluated for lot-to-lot consistency, content of process-relevant impurities, and absence of trace metals which may propagate downstream.
Our process route reflects a compromise among yield, purity profile, and operational safety. We sustain reactive intermediate isolation under inert atmosphere and control temperature to preserve trifluoromethyl integrity. Plant quality systems track process deviations to flag any risk to downstream purity.
Critical steps include intermediate purification, water content control during workup, and isolation atmosphere, with close analytical monitoring for hydrolysis byproducts unique to M-TFPA. Final quality hinges on both chemical purity and physical handling controls.
Impurity sources arise from starting material variability, minor side reactions, and potential solvent exchanges. Purification strategy combines recrystallization and distillation, guided by customer-specific chromatographic fingerprinting. Release criteria lock to both internal tolerances and application-specific guidance, aided by retained sample archiving for lot history traceability.
Our production facility applies ISO-aligned quality management practices for all grades of Methyl 3,3,3-trifluoropyruvate. Audits cover material traceability, batch integrity, deviation investigation, and documentation management. Oversight addresses both process route selection and change management during production transitions. Supply chains for raw fluorinated intermediates are monitored for origin, consistency, and typical impurity profiles that impact final product stability.
Depending on end-use and region, certain grades of M-TFPA align with required registrations and market expectations, such as industrial, R&D, or electronic chemical compliance. For pharmaceutical or advanced materials applications, release protocols incorporate specific agreement on test criteria and impurity thresholds, defined jointly with customer quality teams. Each batch is released upon meeting documented customer-specific specifications in addition to routine manufacturer criteria.
Standard shipments include a certificate of analysis featuring routinely controlled parameters: assay, origin, water content, color, residual acidity, and grade-dependent tracers. For material released under a special agreement, the certificate covers customer-specific elements such as enantiomeric purity or spectroscopic reports. Regulatory dossiers and analytical method validations are available for advanced customers upon request, subject to confidentiality and grade assignment.
M-TFPA volume availability depends on both core and campaign-based production routes. For sustained supply, preferred collaboration covers rolling forecasts or frame contracts. Account managers and technical specialists coordinate scheduling and capacity utilization based on project timelines and downstream project risks, ensuring minimized risk of sourcing gaps.
Production capacity reflects both continuous and campaign batch system output, with scalability tied to precursor shipment reliability and purification throughput. Grade selection impacts available batch sizes and process sequencing—higher-purity, customer-qualified grades often require discrete campaign planning to control cross-contamination. Release timing follows quality sign-off, holding protocols, and customer notification cycles.
Sample requests receive technical review to align grade, volume, and documentation with intended use. Standard evaluation packs feature full batch traceability, CoA, and, depending on the agreement, reserve samples for future re-testing. Pre-shipment consultation allows for technical dialogue on analytical requirements or unusual handling needs, especially for R&D formulations or special impurity profiles.
Customers seeking dual-sourcing security or project-based delivery schedules often coordinate specialized call-off protocols. Multi-region projects may trigger alternative packaging or multi-modal shipment planning, tailored to site capabilities and regulatory constraints. For long-term development partnerships, joint technology transfer and process optimization workshops are arranged with customer technical staff to address unique requirements and anticipate scale-up challenges.
Ongoing R&D efforts for M-TFPA are primarily driven by demand in pharmaceutical synthesis and advanced agrochemical intermediates. Researchers focus on downstream applications involving selective trifluoromethylation—a reaction class often limited by the availability and purity of feedstock like M-TFPA. Optimization protocols target yield improvement, purity benchmarks, and by-product minimization, with current interest on catalytic pathways and milder reaction conditions to boost selectivity for pharmaceutical building blocks.
Outside classical pharmaceutical and agrochemical routes, R&D has identified polymer modification and fluorine-containing fine chemicals as areas with growth potential. Academic-industry collaborations sometimes evaluate M-TFPA’s performance in synthesis of bioactive molecules, leveraging the electron-withdrawing effects of the trifluoromethyl group for target molecule stability or enhanced biological profile. Application-sensitivity is observed in final molecule performance depending on precursor grade (pharma, technical), influencing downstream isolation or formulation outcomes.
Scalability remains a consistent challenge. Trace impurities—frequently generated from side reactions involving raw material batch variability or reactor “hot spots”—must be managed rigorously, especially in pharma-grade production. Techniques advancing impurity profiling (chromatographic fingerprinting, advanced mass spectrometry) help define release standards on a lot-by-lot basis. Continuous flow synthesis represents a technical breakthrough, showing promise for tighter process control, thermal management, and consistent batch outputs. Further progress is expected from tailored ligand or catalyst development, targeting more efficient carbon-fluorine bond construction under industrial conditions.
Demand outlook remains robust, prompted by the sustained growth of fluorinated pharmaceuticals and global pesticide development. Regional surges can link to regulatory updates or shifts in API manufacturing bases. Across regions, the uptake diverges depending on regulatory acceptance, available downstream technology, and degree of vertical integration (in-house vs. buyer’s own synthesis). Tonnage is expected to show CAGR in line with global specialty chemical indexes, but actual figures depend on capacity expansions and successful debottlenecking projects by key producers.
Evolution in M-TFPA production emphasizes modular plant design, digital batch monitoring, and feedback-controlled purification. Key process improvements focus on solvent recovery, closed-loop handling, and discharge minimization for process water and solvent streams. Ongoing implementation of inline analytical feedback is impacting real-time quality assurance, supporting faster release decisions and tighter impurity tracking per market specification.
Sustainability initiatives focus on solvent load reduction, transition to greener alternatives where route-compatible, and minimization of perfluorinated by-products in synthesis and work-up. Waste recovery is managed both by solvent distillation cycle efficiency and targeted recycling of side streams. Producer-region regulations increasingly encourage non-halogenated auxiliaries or the adoption of decarbonized power for heating/condensing steps during production. Market preference is rising for grades with lifecycle documentation on emissions and waste handling, particularly among EU and North American customers.
Dedicated technical service teams support customer project evaluation, with focus on reaction compatibility, process yield optimization, and impurity interaction. Consultation often includes assessment of grade alignment with end-use (GMP, technical, or research scale demands). Feedback loops with customers inform process adjustments or product qualification for new applications.
Support extends to joint process troubleshooting, scale-up risk assessment, and analytical method transfer assistance. Manufacturers provide guidance on storage stability, container compatibility, and environmental controls as determined by specific product grade and logistics route. Where downstream processing demands low levels of residual raw material or specific impurity profiles, analytical support is provided to establish joint release criteria.
After-sales support comprises batch-to-batch traceability, documentation on quality control lots, and technical investigation for any reported deviation from specification. Comprehensive record-keeping enables traceback and root-cause analysis in the event of unexpected outcomes during customer processing. For regulated markets, support includes documentation matching local registration or regulatory audit requirements, with full change control notification if synthetic route or specification baselines are revised.
At our facility, we manufacture Methyl 3,3,3-trifluoropyruvate (M-TFPA) using a tightly controlled process that delivers material to meet exacting industrial and scientific expectations. Over years of development, our production infrastructure has positioned us as the direct source for M-TFPA serving fine chemical synthesis, pharmaceutical research, and advanced materials industries.
M-TFPA plays a unique role in pharmaceutical intermediate synthesis, fluorinated building blocks, and specialty chemical research projects. Customers rely on this molecule when developing new active ingredients, high-performance coatings, and agrochemical innovations. M-TFPA’s trifluoromethyl moiety provides performance advantages, including increased metabolic stability and altered physicochemical properties—features central to driving new product development in competitive R&D environments.
We maintain in-house analytical laboratories equipped with NMR, HPLC, and GC-MS to ensure each batch meets established chemical purity and physical characterization benchmarks. Our plant technicians calibrate processes routinely, eliminating surprise batch-to-batch differences. Traceability starts from raw material selection and ends with shipment-ready product. Industrial users managing process validation, regulatory submissions, or high-throughput screening do not face uncertainty over supply interruptions, as our quality controls address impurities and off-spec material at every step.
To accommodate high-volume and pilot-scale consumers, we offer M-TFPA in sealed, approved containers ranging from small packs for lab applications through to ISO drum lots for industrial synthesis lines. Packaging is designed to prevent contamination and minimize losses in volatile and moisture-sensitive transfers. Secure encapsulation and transport logistics protect against product degradation throughout global shipments. We monitor order trends in real-time and align production slots for both just-in-time requests and standing blanket orders.
Direct dialog between our technical staff and our customers enables practical, case-by-case guidance for chemical engineers, formulators, and project leads. Support extends to recommendations on storage, handling conditions, and downstream synthetic compatibility based on real experience at scale. Buyers implementing continuous production or scale-up benefit from our history of troubleshooting and technical insight derived from actual process data and field feedback.
Businesses selecting our M-TFPA gain more than material—they benefit from sourcing predictability, price transparency, and stable supply channels. Distribution partners stay in sync with our planned output cycles, while manufacturers integrating M-TFPA into pipelines minimize the risks and delays caused by specification drift or uncertain origins. Procurement teams focused on performance metrics and regulatory compliance find confidence in documentation, batch records, and responsive supply chain management at every contract stage. Our approach reduces total landed cost and supports the consistent roll-out of end products across multiple markets.
Our experience working with Methyl 3,3,3-trifluoropyruvate over the years has shown its distinctive character begins at the molecular level. The compound’s structure integrates a highly electronegative trifluoromethyl group attached to a pyruvate backbone. This arrangement drives two features we observe in production and finished form: striking reactivity in nucleophilic addition reactions and pronounced electron-withdrawing behavior. As a result, M-TFPA stands out as a stable, colorless to slightly yellow liquid under controlled conditions, comfortably managed with standard chemical processing precautions.
Its measurable solubility in most polar organic solvents and reliable boiling point grant chemists more flexibility with reaction conditions. We manufacture our M-TFPA following strict quality parameters to maintain high purity, so it consistently delivers predictable reaction outcomes. Over time, the stability we ensure by minimizing moisture and oxygen exposure pays dividends for our downstream partners who count on repeatability.
We have supplied M-TFPA to chemical, pharmaceutical, and fine chemical companies focused on synthetic research. Its trifluoromethyl group piques interest in medicinal chemistry due to its ability to modify both the metabolic stability and the lipophilicity of active molecules. For teams synthesizing fluorinated building blocks or exploring enzyme inhibitors, M-TFPA supports early and intermediate steps that open up novel molecular architectures. Our customers value this reliability when optimizing new drug candidates or agrochemical solutions.
Organic synthesis consistently draws on the compound’s reactivity for enolate alkylation, aldol reactions, and Michael additions. By leveraging our stable supply, research groups can streamline lead optimization. In some settings, M-TFPA even serves as an efficient precursor for trifluoromethylated alpha-keto acids or other functionally dense intermediates. We monitor feedback from these teams to improve our process and reduce batch-to-batch variability. That vigilance is especially important given the growing complexity of targeted molecules in specialty synthesis.
For industrial and materials research, M-TFPA increasingly finds its place in the development of robust ligands and catalysts. Its electronic properties lend themselves well to fine-tuning catalytic systems. We understand these requirements and accommodate custom packaging or delivery formats for pilot plant and scale-up work. Such adaptability ensures that material arrives in top condition, matched to the researcher’s workflow.
Working as the direct manufacturer, our technical team addresses challenges that may arise with M-TFPA. For instance, accidental exposure to atmospheric moisture can lead to hydrolysis and diminish shelf life. To counter this, our standard packaging features barrier protection and inert gas blanketing. Customers working with demanding synthesis routes can tap into our process know-how—whether pinpointing purification difficulties or discussing optimal storage. The close relationship with end-users gives us insight that shapes process improvements back at our facilities.
M-TFPA will continue earning notice for its synthetic power and versatility. By investing in robust supply chains and technical support, we put trusted materials in the hands of innovators working at the edge of modern chemistry.
Manufacturing M-TFPA means closely following the real-world needs that chemists, R&D labs, and production teams face every day. Chemical handling requirements are never one-size-fits-all. We pack M-TFPA based on years working with both high-volume and research-scale users. For customers requesting laboratory scale, our smallest jugs typically start at one kilogram. Common requests fall in the 5 kg and 25 kg range as well. Bulk manufacturing customers often choose drum or lined fiberboard container options in 50 kg or 100 kg units. For full tanker loads or intermediate bulk containers (IBCs), we use heavy-gauge lined drums or liquid bins, which we assemble and inspect on-site for every order.
Industrial, electronics, and pharmaceutical production all set distinct targets for M-TFPA purity. Running a clean process link is key in downstream chemistry and electronics etching. We consistently supply M-TFPA at 98% minimum purity for most commercial applications. For customers operating under more demanding standards—semiconductor or custom synthesis—our purification lines can deliver much higher purities. Each lot comes with a full batch certificate tracing critical elements, trace metals, and moisture content. Staff chemists audit the purification train and lab instrumentation against standard operating procedures, aiming for process repeatability.
Meeting large-scale demand means planning and infrastructure. We manufacture M-TFPA using a continuous process, always targeting a minimum buffer stock to serve repeat orders from industrial or multinational clients. The plant’s scheduling covers high-volume requests. When customers specify a preferred grade or container, our packaging line adapts. Whether the order is for a single drum or several thousand kilograms monthly, we run production shifts around the agreed delivery timeframe. With logistics staff on-site, we coordinate direct freight and export packing. Many large accounts request contract supply plans—our commercial team sets these up with clear volume agreements and buffer stock for surge requirements.
We design every package around the physical properties of M-TFPA. It’s tightly moisture-controlled material, so we use sealed liners and industrial closures to avoid contamination even while in storage or transit. Drum loads get palletized and secured by industrial strapping. For bulk containers, we attach tracking and inspection documentation so every lot remains traceable. Before shipment, we double-check every filled container against production logs and sample the material again to guarantee quality.
Experience counts. Over the years, we have fine-tuned not only M-TFPA production itself, but also the practicalities of transfer, dilution, and processing. Customers aiming for scale-up or with custom end-use requirements often work directly with our technical teams. We share lot data, purity specs, and handling recommendations. For new applications, support includes pilot sample production or on-site troubleshooting when M-TFPA gets introduced into a new production line.
We reinvest in our plant with better purification systems and quality audit capabilities. Input from industrial users and feedback from laboratory customers both matter as we improve materials and logistics each year. Manufacturing M-TFPA in-house means every package, drum, or shipment carries our direct accountability. No third-party steps, no outsourcing of oversight. Our company stands behind each delivery, and we invite technical questions about purity, shelf life, compatibility, or regulatory needs. This approach has enabled us to supply M-TFPA at an industrial scale, with confidence in every drum and every kilogram that leaves our warehouse.
M-TFPA moves through our operations under strict controlled conditions. As direct producers, we pay close attention from synthesis to bulk packing. The compound’s reactivity, combined with its chemical classification, gives us zero margin for error in housekeeping. Our team starts with thorough risk analysis. Each pallet, drum, and bag in our inventory sits in a location suitable for its hazard status, well away from incompatible materials or untrained personnel.
In-house, we stick to isolation strategies. Designated storage zones keep containers protected from temperature extremes, moisture, and light. We rely on closed, labeled packaging. Our containers—mostly steel or high-density polyethylene—never double as makeshift storerooms for other products. Every release or spill scenario points to the need for solid secondary containment. Our operations maintain adequate ventilation and controlled access to eliminate risks associated with vapors or accidental mixing. Fire safety infrastructure sits ready at every step, reflecting lessons we’ve learned from years of managing regulated materials.
All staff working with M-TFPA finish comprehensive chemical handling training before day one. Our standard operation procedures call out splash protection and full respiratory coverage for exposure-prone tasks. Gloves, goggles, and impervious protective gear stay readily available across processing and handling lines. Direct transfers between our reactors and filling systems take place in closed environments, minimizing worker contact and environmental release. Regular maintenance and equipment inspections reduce breakdowns, while records of each handling event stand ready for internal audits or regulatory inspection. We test every PPE batch before use, mainly to head off degradation or permeability failures that could surface with highly active materials.
We package all outbound M-TFPA shipments to meet international and local dangerous goods standards, whether shipping on land, sea, or air. Our drums bear clearly visible hazard labels referencing the correct transport classification. Every consignment carries a multi-language Safety Data Sheet authorized by our technical compliance staff. Freight partners receive detailed handling notes directly from our logistics team—never left to guesswork or informal third-party advice. Seals and closures on containers stand up to vibration, pressure changes, and stacking forces encountered in real transit conditions. Emergency contact and spill protocols travel with the product, not buried in a shipment manifest.
Our technical and EH&S units review incident data from international peers and regulatory bodies to refine our internal code. We consider inputs from lab, floor, and drivers’ cab—directly from those working hands-on with the product. Where bottlenecks or potential hazard trends emerge, we test solutions in our own batch environment before rollout across facilities. As regulations adapt, we ensure all labels, documents, and procedures match fresh requirements before shipment leaves the factory. If standards call for additional containment systems or enhanced PPE, we procure and commission them without hesitation. We keep our workforce well briefed and resupplied, and we invite feedback from all corners of our supply chain.
We do not take shortcuts because the risks never justify a cost saving. Every pack that leaves our site reflects the experience of managing high-hazard substances across decades of production. Meeting legal regulations forms the baseline — we invest further to guarantee safe outcomes for everybody who touches M-TFPA, from our loading dock to your inventory shelf. Our safety, compliance, and transport protocols evolve as science and regulation move forward. Questions on our procedures or documentation can be answered by our technical team, who work directly with these materials daily.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales9@bouling-chem.com, +8615651039172 or WhatsApp: +8615651039172
